DNA icon

Hereditary Paraganglioma-Pheochromocytoma Syndrome via the SDHB Gene

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
7093 SDHB 81405 81405,81479 $640 Order Options and Pricing
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
7093SDHB81405 81405(x1), 81479(x1) $640 Order Options and Pricing

Pricing Comments

This test is also offered via our exome backbone with CNV detection (click here). The exome-based test may be higher priced, but permits reflex to the entire exome or to any other set of clinically relevant genes.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Turnaround Time

18 days on average for standard orders or 13 days on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.

EMAIL CONTACTS

Genetic Counselors

Geneticist

  • Hannah Cox, PhD

Clinical Features and Genetics

Clinical Features

Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome is a familial cancer syndrome that results in neuroendocrine tumors. The diagnosis of hereditary PGL/PCC syndrome is based on physical examination, family history, imaging studies, biochemical testing, and molecular genetic testing. Symptoms of PGL/PCC result either from mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, palpitations, pallor, and apprehension or anxiety; Klein and Lloyd. GeneReviews. 2009). Paraganglia are a group of neuroendocrine cells that originate from the embryonic neural crest and can secrete catecholamines. In the PGL/PCC syndrome, paraganglia arise in either the paravertebral axis (base of the skull to the pelvis) for paragangliomas or the adrenal medulla for pheochromocytomas (Welander et al. Endocrine-Related Cancer 18:R253–R276, 2011). Sympathetic paragangliomas hypersecrete catecholamines, whereas parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the head and neck and most often are nonsecretory. The sympathetic extra-adrenal paragangliomas are generally located in the thorax, abdomen, and pelvis and are usually secretory. Pheochromocytomas typically hypersecrete catecholamines (Klein and Lloyd. GeneReviews. 2009). The prevalence of PGL/PCC tumors in the United States has been estimated to be between 1:2500 to 1:6000 (Chen et al. Pancreas 39:775–783, 2010) and for the hereditary PGL/PCC syndrome has been estimated at 1:25,000 to 1:50,000 (Welander et al., 2011).

Genetics

Hereditary paraganglioma-pheochromocytoma syndrome is an autosomal dominant disorder and is mainly caused by variants in three genes (SDHD, SDHC, and SDHB), which are known by their syndromic names PGL1, PGL3, and PGL4. Hereditary PGL/PCC syndrome presents variable expressivity and age-related penetrance. SDHA, SDHB, SDHC, and SDHD are nuclear genes that encode the four subunits of the mitochondrial enzyme succinate dehydrogenase (SDH). Another gene, SDHAF2 (also known as SDH5) encodes a protein that appears to be required for flavination of the SDHA subunit. (Kirmani and Young 2012; Welander et al. 2011).

Clinical Sensitivity - Sequencing with CNV PG-Select

Although the majority of PGL/PCC tumors are sporadic (non-familial), approximately 13% of PGL/PCC tumors are caused by germline variants in the known PGL/PCC syndrome genes (Welander et al. Endocrine-Related Cancer 18:R253–R276, 2011). Variants in the SDHB gene are detectable in up to 24% of hereditary PGL/PCC cases depending on the tumor’s location. PGL/PCC tumors can also be found in 10% of other familial syndromes such as multiple endocrine neoplasia type 2 (MEN2), von Hippel–Lindau disease (VHL), and neurofibromatosis type 1 (NF1); they are seen less often in Carney triad and Carney–Stratakis syndrome and rarely in multiple endocrine neoplasia type 1 (MEN1; Welander et al., 2011). In addition to the PGL/PCC syndrome genes, germline variants in a number of other genes may also predispose to PGL/PCC tumors (Opocher et al. Best Practice & Research Clinical Endocrinology & Metabolism 24:943–956, 2010). Large deletions in SDHB have been reported in 12% of patients (Cascón et al. Genes Chromosomes Cancer 45:213–9, 2006).

Testing Strategy

This test provides full coverage of all coding exons of the SDHB gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.

Indications for Test

Individuals with a history of hereditary PGL/PCC syndrome. People with a family history of hereditary PGL/PCC syndrome should be tested early (<10 years of age). Hereditary PGL/PCC syndrome should be considered in all individuals with paragangliomas or pheochromocytomas, especially those with multiple, multifocal, recurrent or early-onset tumors (i.e., <40 years; Young. Williams Textbook of Endocrinology, 11 ed. pp.:505-537, 2008). This test is specifically designed for heritable germline variants and is not appropriate for the detection of somatic variants in tumor tissue.

Earlier diagnosis may improve patient prognosis through regular screening and treatment for early-onset malignancies. Early detection through surveillance and removal of tumors may prevent or minimize complications related to mass effects, catecholamine hypersecretion, and malignant transformation.

Gene

Official Gene Symbol OMIM ID
SDHB 185470
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Related Tests

Name
Hereditary Neuroblastoma via the KIF1B Gene
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the MAX Gene
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the SDHA Gene
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the SDHAF2 Gene
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the SDHC Gene
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the SDHD Gene
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the TMEM127 Gene
Mitochondrial Complex II Deficiency Panel
Renal Cancer Panel

Citations

  • Cascón et al. (2006). "Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot?" Genes Chromosomes Cancer 45:213–9. PubMed ID: 16258955
  • Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K. 2010. The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer. Pancreas 39: 775–783. PubMed ID: 20664475
  • Kirmani S, Young WF. 2012. Hereditary Paraganglioma-Pheochromocytoma Syndromes. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, Smith RJ, and Stephens K, editors. GeneReviews™, Seattle (WA): University of Washington, Seattle. PubMed ID: 20301715
  • Opocher G, Schiavi F. 2010. Genetics of pheochromocytomas and paragangliomas. Best Practice & Research Clinical Endocrinology & Metabolism 24: 943–956. PubMed ID: 21115163
  • Welander J, Soderkvist P, Gimm O. 2011. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine Related Cancer 18: R253–R276. PubMed ID: 22041710
  • Young. Williams Textbook of Endocrinology, 11 ed. Pp.:505-37, 2008

Ordering/Specimens

Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page


Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×

ORDER OPTIONS

View Ordering Instructions

1) Select Test Method (Backbone)


1) Select Test Type


2) Select Additional Test Options

STAT and Prenatal Test Options are not available with Patient Plus.

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: $
×
Copy Text to Clipboard
×